Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)

NCT02829840 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Conditions

Leukemia
FLT3-Mutated Acute Myeloid Leukemia
FLT3-Mutated High-Risk Myelodysplastic Syndrome

Interventions

DRUG: Ponatinib
DRUG: 5-azacytidine
BEHAVIORAL: Phone Calls

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]